



ASX & MEDIA RELEASE

18 SEPTEMBER 2017

## **MEDLAB GRANTED 20 YEAR AUSTRALIAN PATENT FOR IT'S ANTI-DEPRESSION PRODUCT – NRGBiotic™**

- **Granted 20 year Australian patent for Medlab's NRGBiotic™ product**
- **Approval process for patent under way for other global markets, USA, Europe and 2 Asian Countries**
- **Medlab's NRGBiotic demonstrates significant enhancement for depression sufferers, thus exponentially adding to commercial potential**
- **According to the World Health Organisation (WHO), 350m people world-wide suffer from depression**
- **The Australian Government spends \$564M per annum on subsidised anti-depressant medicines**

Medical life science company, Medlab Clinical Limited (ASX: MDC), has been granted a 20 year patent covering the Australian market for its probiotic product, NRGBiotic™.

Applications for patents in the United States, Europe and two Asian countries are also under way.

According to Medlab CEO, Sean Hall, achieving a patent for NRGBiotic™, independently validates an important pillar of Medlab's science.

"To be granted a patent on our NRGBiotic™ product, Medlab needed to show uniqueness, usefulness and effectiveness," Sean Hall said.

Prof Luis Vitetta, Director of Medical Research at Medlab, said "It's a sad fact that for about one-third of patients with an on-going diagnosis of depression, that the success rate with standard medication is limited; our product, NRGBiotic™ enhances the effect of standard medication."

### **Incidence of depression and market**

Depression is the leading cause of disability worldwide.

In Australia, the Australian Bureau of Statistics reports that in 2014-15, 2.1 million people or 9.3% of the population suffer from depression.<sup>1</sup>

In 2015-16, the Australian government spent \$564 million, or \$24 per person, on subsidised depression prescriptions.<sup>2</sup>

According to the World Health Organisation, depression will be the highest level of disability of any physical or mental disorder by 2030, with it currently affecting 350 million people worldwide or 5% of the world's population.<sup>3</sup>

---

<sup>1</sup> <http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/by%20Subject/4364.0.55.001~2014-15~Main%20Features~Mental%20and%20behavioural%20conditions~32>

<sup>2</sup> <https://mhsa.aihw.gov.au/resources/expenditure>

<sup>3</sup> [http://apps.who.int/gb/ebwha/pdf\\_files/EB130/B130\\_9-en.pdf](http://apps.who.int/gb/ebwha/pdf_files/EB130/B130_9-en.pdf)

In 2015, an estimated 16 million adults in the United States had at least one major depressive episode in the previous year, with this number representing 6.7 per cent of all U.S. adults.<sup>4</sup>

Mr Michael Hall, Chairman of Medlab said “the granting of the NRGBiotic patent is a major breakthrough for the Company, confirming the company’s belief that the use of specific probiotic strains is an important co-therapy in managing chronic diseases, and significantly increases revenue opportunities. While this announcement relates to Probiotics, Shareholders should remember that Medlab has TWO pillars of Research:

- Probiotics and gut health
- Nanocelle™ – our patented delivery platform

We are currently progressing our human trials on schedule:

- NanoCelle™ Statin being compared to market leader – Global Statin market forecast to be US\$12 billion in 2018<sup>5</sup>
- NanaBis™ (THC/CBD) cannabis trial for advanced oncology patients with intractable pain
- NanaBidal™ (CBD only) cannabis trial for patients with nausea, vomiting and seizures

More can be found in our prior announcements,” Michael Hall said.

---

**ISSUED FOR:** MEDLAB CLINICAL LTD (ASX: MDC) – [www.medlab.co](http://www.medlab.co)

**FOR FURTHER INFORMATION:** SEAN HALL, CEO, MEDLAB CLINICAL  
TEL: +61 2 8203 9520, [sean\\_hall@medlab.co](mailto:sean_hall@medlab.co)

**ISSUED BY:** HILL + KNOWLTON STRATEGIES, MARCHA VAN DEN HEUVEL  
TEL +61 2 9286 1226 OR +61 468 960 457, [marcha.vandenheuvel@hkstrategies.com](mailto:marcha.vandenheuvel@hkstrategies.com)

**ABOUT MEDLAB – [www.medlab.co](http://www.medlab.co)**

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, Nanocelle™, is being applied to its medicines, nutritional products and off-patent drugs like statins. Medlab has a growing patent portfolio.

---

<sup>4</sup> <https://www.nimh.nih.gov/health/statistics/prevalence/major-depression-among-adults.shtml>

<sup>5</sup> <http://www.prweb.com/releases/statins-drugs-market/analysis-forecast-2018/prweb10367278.htm>